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Perspectives in Diabetes
Autonomic Mediation of Glucagon Secretion 
During Hypoglycemia
Implications for Impaired -Cell Responses in 
Type 1 Diabetes
Gerald J. Taborsky Jr, Bo Ahrén, and Peter J. Havel
This article examines the role of the autonomic nervous
system in mediating the increase of glucagon secretion
observed during insulin-induced hypoglycemia (IIH).
In the first section, we briefly review the importance of
the -cell response in recovery from hypoglycemia
under both physiologic conditions and pathophysio-
logic conditions, such as type 1 diabetes. We outline
three possible mechanisms that may contribute to
increased glucagon secretion during hypoglycemia but
emphasize autonomic mediation. In the second section,
we review the critical experimental data in animals,
nonhuman primates, and humans suggesting that, in
the absence of diabetes, the majority of the glucagon
response to IIH is mediated by redundant autonomic
stimulation of the islet -cell. Because the glucagon
response to hypoglycemia is often impaired in patients
with type 1 diabetes, in the third section, we examine
the possibility that autonomic impairment contributes
to the impairment of the glucagon response in these
patients. We review two different types of autonomic
impairment. The first is a slow-onset and progressive
neuropathy that worsens with duration of diabetes,
and the second is a rapid-onset, but reversible, auto-
nomic dysfunction that is acutely induced by
antecedent hypoglycemia. We propose that both types
of autonomic dysfunction can contribute to the
impaired glucagon responses in patients with type 1
diabetes. In the fourth section, we relate restoration of
these glucagon responses to restoration of the auto-
nomic responses to hypoglycemia. Finally, in the fifth
section, we summarize the concepts underlying the
autonomic hypothesis, the evidence for it, and the
implications of the autonomic hypothesis for the treat-
ment of type 1 diabetes. D i a b e t e s 4 7 :9 9 5–1005, 1998
GLUCAGON SECRETION DURING HYPOGLYCEMIA: 
CLINICAL IMPORTANCE AND POTENTIAL MECHANISMS
Clinical importance. Hypoglycemia is a major acute com-
plication of type 1 diabetes, contributing to both its morbid-
ity and its mortality (1). Attempts to reduce the long-term
complications associated with type 1 diabetes, such as
retinopathy and nephropathy, by reducing hyperglycemia via
intensive insulin therapy have unfortunately exacerbated this
acute complication: intensive insulin therapy produces a
threefold increase of the incidence of severe hypoglycemia
(2,3). For this reason, hypoglycemia is a major limiting fac-
tor in improving glycemic control (4) and, therefore, in pre-
venting or reducing the long-term complications associated
with type 1 diabetes. Consequently, it is important to under-
stand the physiologic mechanisms that limit the severity and
duration of hypoglycemic episodes.
The work of Gerich and Cryer (5,6) established the impor-
tance of glucagon and epinephrine in limiting the glucose
nadir and promoting rapid recovery of plasma glucose from
rapid and transient hypoglycemia in nondiabetic human sub-
jects. Later studies, primarily by Bolli et al., also suggested
important roles for glucagon (7) and epinephrine (8) in coun-
tering the slow-onset, but progressive, hypoglycemia that is
more often encountered clinically (9). Because most patients
who have had type 1 diabetes for 1–2 decades have totally lost
their glucagon response to IIH and have blunted epinephrine
responses, these studies helped to explain the impairment of
glucose recovery observed in patients with long-term type 1
diabetes (10–14). In many patients with newly diagnosed
type 1 diabetes, both glucagon and epinephrine responses to
hypoglycemia are quantitatively normal, as is the rate of glu-
cose recovery from hypoglycemia (15). In contrast, many
patients who have had type 1 diabetes for less than a decade
have blunted glucagon responses with normal epinephrine
responses, but a delayed glucose recovery (15). From these
studies, the concept emerged that the glucagon response is
critical for normal glucose recovery and that impairment of
the glucagon response is a major factor in the susceptibility
of patients with type 1 diabetes to episodes of prolonged
and severe hypoglycemia (5). Thus, it became important to
understand the mechanisms that mediate the normal
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glucagon response to hypoglycemia and to determine how
these mechanisms are compromised in type 1 diabetes.
Potential mechanisms. Three different mechanisms have
been proposed to mediate the -cell response to hypogly-
cemia (Fig. 1). The first is straightforward, namely, that
hypoglycemia directly stimulates glucagon secretion from
the pancreatic -cell. In support of this hypothesis are in
vitro experiments in which perfusion of the isolated pan-
creas with low-glucose media increased glucagon secre-
tion (16). However, this type of experiment may not be as
conclusive as it appears, since hypoglycemia also lowers
insulin secretion, which can also have effects on the -cell.
Indeed, lowering the glucose level to which isolated - c e l l s
are exposed failed to stimulate glucagon secretion (17),
suggesting little direct stimulatory effect of hypoglycemia
per se on the -cell. It remains unclear how much of the
glucagon response in vivo is mediated by glucose recogni-
tion directly by the -cells.
A second mechanism that could potentially mediate
increased glucagon secretion in response to hypoglycemia
involves a local inhibitory effect of endogenous insulin on
neighboring -cells (Fig. 1). Such an action of endogenous
insulin was originally proposed by Samols (18), first strongly
supported by the extensive data of Weir (19), and later crit-
ically reviewed by both (20). This mechanism requires that
blood within the islet flows from -cells to the - c e l l s ,
thereby exposing them to high concentrations of intraislet
insulin, a concept that has both anatomical (21) and physi-
ological (22,23) support. It also requires that insulin or a -
cell product directly inhibit glucagon secretion from the -
cell. Marked inhibition by insulin has been demonstrated in
hamster glucagonoma cells (22), but only modest inhibition
has been demonstrated in normal purified rat -cells (17),
which apparently lack insulin receptors (24). Thus, other -
cell products, such as gamma aminobutyric acid (25), might
also mediate the inhibitory effect of the -cell on the - c e l l .
A l t e r n a t i v e l y, high concentrations of intraislet insulin could
cross-react with the IGF-1 receptors found on -cells (26).
Whatever the mediator, hypoglycemia would inhibit secretion
from the -cell and thereby remove the tonic local inhibitory
restraint on the -cell, resulting in increased glucagon secre-
tion (20,27,28). In vivo, exogenous insulin has been shown
to impair the glucagon response to arginine in patients with
type 1 diabetes who have little endogenous insulin secretion
(29). Endogenous insulin also apparently inhibits glucagon
secretion, at least in vitro. For example, neutralizing endoge-
nous insulin by perfusion of the isolated pancreas with high
titer anti-insulin antibodies increases glucagon secretion in
a variety of species (22,30). Also, destruction of islet - c e l l s
prevents low glucose media from stimulating glucagon
secretion in vitro (31). Thus, a role for intraislet insulin or a
-cell product in the glucagon response to hypoglycemia is
supported by a variety of in vitro data. Its role in vivo is less
c l e a r, however: when endogenous insulin secretion is par-
tially suppressed before hypoglycemia in nondiabetic
humans, there is still a quantitatively normal -cell response
to hypoglycemia (32). Similarly, patients with newly diag-
nosed type 1 diabetes, who presumably have markedly
reduced endogenous insulin secretion, also exhibit a normal
increase of glucagon secretion in response to hypoglycemia
(32). Thus, either suppression of endogenous insulin is not
the mediator of the glucagon response to hypoglycemia in
vivo, or complete suppression of endogenous insulin secre-
tion, as seen only during hypoglycemia (32), is necessary to
stimulate glucagon secretion (see G L U C A G O N R E S P O N S E f o r
further discussion).
A third potential mediator of the glucagon response to
hypoglycemia is the autonomic input to the -cell (33) (Fig.
1). There are three major autonomic inputs to the -cell:
sympathetic nerves, parasympathetic nerves, and the cir-
culating neurohormone epinephrine (Fig. 2). Inclusion of epi-
nephrine as part of the autonomic response to hypogly-
cemia is consistent with its established role as a key medi-
ator of the metabolic effects of sympathetic activation
during other stresses (34).
All three of these autonomic inputs to the - c e l l — s y m p a-
thetic nerves, parasympathetic nerves, and adrenal medulla—
are activated by hypoglycemia (33). Cannon first demon-
996 DIABETES, VOL. 47, JULY 1998
AUTONOMIC NERVOUS SYSTEM AND GLUCAGON
FIG. 1. Nondiabetic subjects. A: During euglycemia, glucagon secretion
may be tonically restrained (thin arrow) by 1) a mild inhibitory eff e c t
(–) of glucose directly on the -cell, 2) the lack of autonomic stimu-
lation of the -cell, and 3) a marked inhibitory effect (– – –) of
endogenous insulin on the -cell. B: During hypoglycemia, glucagon
secretion is markedly increased (thick arrow), perhaps by 1) a direct
stimulatory effect (+) of hypoglycemia on the -cell, 2) a marked
stimulatory effect (+ + +) of the autonomic nervous system secondary
to its activation by central hypoglycemia, and 3) a marked reduction
of endogenous insulin (thin arrow), and thus its inhibitory effect on
the -cell. These stimulatory effects overwhelm any inhibitory eff e c t
(–) of exogenous insulin directly on the -cell. The marked reduction
of endogenous insulin secretion is secondary to 1) an inhibitory eff e c t
(–) of exogenous insulin per se on the -cell, 2) an inhibitory eff e c t
(–) of hypoglycemia directly on the -cell, and 3) a net inhibitory
e ffect (– – –) of the autonomic input to the -cell. - and -cells are
represented as circles labeled A and B, respectively.
A
B
strated over 70 years ago that hypoglycemia stimulates the
secretion of epinephrine from the adrenal medulla. In con-
trast, the activation of pancreatic sympathetic nerves by
hypoglycemia has only recently been demonstrated (35,36).
The demonstration that parasympathetic nerves to the pan-
creas are activated during hypoglycemia is indirect: atropine
blocks the hypoglycemia-induced secretion of pancreatic
polypeptide (PP) from the islet F-cell (33,37).
Each of these three autonomic inputs to the -cell is capa-
ble of stimulating glucagon secretion (33). Epinephrine stim-
ulates glucagon secretion both in vitro (38) and in vivo (39).
Electrical stimulation of pancreatic sympathetic nerves (40)
or local infusion of the classical sympathetic neurotransmit-
ter norepinephrine (41) or a pancreatic sympathetic neu-
ropeptide, such as galanin (42), all increase glucagon secre-
tion. Finally, electrical stimulation of parasympathetic nerves
(43,44) or local infusion of the classical parasympathetic
neurotransmitter acetylcholine (45) or a pancreatic parasym-
pathetic neuropeptide, such as vasoactive intestinal peptide
(VIP), (46,47) all stimulate glucagon secretion. Thus, three dif-
ferent autonomic pathways can potentially stimulate
glucagon secretion during hypoglycemia via the actions of
several different transmitters (Fig. 2), suggesting the possi-
bility of redundant autonomic mediation.
Although the three mechanisms above have been dis-
cussed separately, there is evidence for autonomic partici-
pation both in the effect of glucose on the -cell in vitro and
in the suppression of insulin secretion in vivo. For example,
in vitro perfusion of the pancreas with low glucose media can
release norepinephrine from the sympathetic nerve terminals
of the pancreas (48), and -adrenergic blockade during such
perfusions nearly abolishes the glucagon response to glu-
copenia (49). Thus, surprisingly, there is evidence for auto-
nomic mediation of glucagon response to glucopenia, even in
vitro. These findings provide an alternative to the interpre-
tation that hypoglycemia directly stimulates the - c e l l .
Evidence in vivo suggests that part of the suppression of
endogenous insulin secretion seen during IIH is due to acti-
vation of the autonomic nervous system. The evidence for the
effect of hyperinsulinemia on endogenous insulin secretion
includes suppression of C-peptide secretion during hyperin-
sulinemic euglycemic clamps (32) (Fig. 1). Animal studies had
suggested that this inhibition of insulin secretion might be par-
tially neurally mediated (50). This interpretation was con-
firmed in humans by the observation that patients receiving
pancreas transplants (51) showed less suppression of
endogenous insulin secretion during hyperinsulinemic
clamps. Furthermore, hypoglycemia specifically activates
the sympathetic nerves to the pancreas in vivo (35), and early
experiments with cross-perfused dog pancreas suggest that
part of the suppression of insulin secretion during hypogly-
cemia is sympathetically mediated (52). Thus, it becomes
difficult to separate the effects of hypoglycemia that are due
to its direct action on the -cell or to its suppression of
endogenous insulin secretion from those that are mediated via
autonomic activation.
AUTONOMIC CONTRIBUTION IN NONDIABETIC 
ANIMALS AND HUMANS
Animal studies. In 1989, when we first reviewed the litera-
ture on autonomic mediation of glucagon secretion during
hypoglycemia (33), the majority of studies in humans were
negative. Furthermore, only two studies conducted in animals,
one in rats (53) and one in calves (54), suggested a signific a n t
autonomic contribution to hypoglycemia-induced glucagon
secretion. We hypothesized that redundant stimulation of
glucagon secretion by the parasympathetic and sympa-
thoadrenal divisions of the autonomic nervous system (Fig.
2) could explain much of the negative data, and we suggested
that new experiments, designed to simultaneously block all
three autonomic inputs to the -cell, would be required to crit-
ically test this hypothesis. One problem with blocking all
three autonomic inputs to the -cell is the redundancy of
postganglionic neurotransmission in pancreatic sympathetic
and parasympathetic nerves. Although there are effective
antagonists for the actions of the classical neurotransmitters,
norepinephrine and acetylcholine, the available antagonists for
the peptidergic neuropeptides, galanin and VIP, are not yet reli-
able in vivo. In contrast, ganglionic neurotransmission seems
predominately mediated by the release of acetylcholine from
preganglionic nerve terminals and its action on the nicotinic
receptors of postganglionic cell bodies, including adrenal
medullary chromaffin cells (Fig. 2). Therefore, we used nico-
tinic antagonists to block autonomic activation and demon-
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FIG. 2. Three autonomic inputs to the -cell. Preganglionic sympa-
thetic nerves (1) travel in the spinal cord releasing acetylcholine
(ACh) from their terminals within the celiac ganglion. The released
ACh acts on nicotinic (N) receptors on postganglionic sympathetic
neuronal cell bodies, which send fibers that innervate the A-cells.
These nerves release norepinephrine (NE) and sympathetic neu-
ropeptides (not shown) at their terminals within the islet. Pregan-
glionic parasympathetic nerves travel in the vagus (2), releasing ACh
from their terminals within intrapancreatic parasympathetic ganglia.
The released ACh acts on N receptors on postganglionic parasympa-
thetic neuronal cell bodies, which send fibers to the -cells. These
nerves release ACh at their terminals within the islet, which acts on
muscarinic receptors (M) on the -cells. They also release parasym-
pathetic neuropeptides (not shown). Preganglionic sympathetic
nerves from the spinal cord innervate the adrenal medulla (3), releas-
ing ACh to activate N receptors on chromaffin cells. Activation of these
receptors stimulates the release of the sympathetic neurohormone epi-
nephrine (EPI), which reaches the -cell via the arterial circulation.
Each of these three autonomic pathways is activated by hypoglycemia.
strated a marked reduction in the glucagon response to hypo-
glycemia in several species (55–58).
Several other studies have provided evidence of central
neural mediation. For example, preventing central, but not
peripheral, hypoglycemia in dogs with selective carotid and
vertebral artery glucose infusions markedly attenuates both
parasympathetic (PP) and sympathoadrenal (epinephrine)
responses to IIH and eliminates the increase of glucagon
seen when the brain and the pancreas are simultaneously
exposed to hypoglycemia (59). Further, lesioning of the ven-
tromedial hypothalamus in rats (60) or microdialysis of glu-
cose into this region (61) significantly impairs both auto-
nomic activation and the glucagon responses to IIH. These
studies demonstrate the necessity of neural activation for
the glucagon response to hypoglycemia in animals.
Other studies in which autonomic inputs were sequen-
tially blocked support the hypothesized redundancy of auto-
nomic stimulation of glucagon secretion during hypogly-
cemia. For example, the increase of plasma glucagon during
IIH in rats was not significantly affected by parasympathetic
cholinergic blockade with methylatropine or by - and -
adrenergic blockade with tolazoline and propranolol, but the
combination of cholinergic and adrenergic blockade
markedly impaired the glucagon response (62). There is addi-
tional evidence for at least partial redundancy between
parasympathetic and sympathoadrenal mechanisms during
marked hypoglycemia in mice (56) and calves (54). More
r e c e n t l y, in dogs, we found that either the direct sympathetic
innervation of the pancreas (63) or adrenal medullary acti-
vation (P.J.H., T.O. Mundinger, G.J.T., unpublished observa-
tions) can mediate an intact glucagon response to marked
hypoglycemia independently of the vagal parasympathetic
input. Therefore, a significant autonomic contribution to
increased glucagon secretion during hypoglycemia has been
documented in nondiabetic animals, and the response
appears to be redundantly mediated by the three autonomic
inputs to the pancreas (Fig. 2).
H o w e v e r, it was not known whether different mechanisms
were operating to regulate glucagon secretion during hypo-
glycemia in humans and other primates or whether the neg-
ative results obtained from the earlier human studies were the
result of an unrecognized redundancy similar to that demon-
strated in animals. Evidence for the latter interpretation is pro-
vided by studies in rhesus monkeys, in which the ganglionic
blocking agent trimethaphan was used to impair autonomic
activation, while allowing systemic hypoglycemia and hyper-
insulinemia. Trimethaphan infusion nearly abolished the
autonomic (epinephrine, norepinephrine, and PP) responses
and reduced the glucagon response to hypoglycemia of 35
mg/dl (1.9 mmol/l) by ~75% (57), indicating that autonomic
activation mediates a substantial portion of the glucagon
response in a primate species. In the same study, high doses
of atropine combined with - and -adrenergic blockade pro-
duced a similar degree of impairment of the glucagon
response. Thus, the glucagon response to hypoglycemia in
nonhuman primates is mediated via activation of the auto-
nomic nervous system, as it is in other animal species.
Human studies. Indirect support for autonomic mediation
of the glucagon response in humans has been provided by
studies of the acute autonomic dysfunction induced by prior
episodes of hypoglycemia (64,65). This phenomenon has
been termed hypoglycemia-associated autonomic failure by
Cryer (4). In brief, two prior episodes of hypoglycemia (50
mg/dl) markedly reduce both parasympathetic activation (PP
response) and adrenal medullary activation (epinephrine
response) to a third episode of hypoglycemia on the follow-
ing day. The two episodes of prior hypoglycemia also
markedly reduce the glucagon response to the third episode
of hypoglycemia (64). Similar data are available from studies
in rats with much longer periods of recurrent hypoglycemia
(66). Because the degree of hypoglycemia in the episodes is
closely matched, it is unlikely that the effect of hypoglycemia
on the islet, either to directly stimulate the -cell or to release
the -cell from tonic local restraint by high levels of intraislet
insulin, was responsible for the impairment of the glucagon
response to hypoglycemia. Rather, we suggest that it is
related to the impairment of the autonomic activation. Thus,
these data indirectly support the hypothesis that the
glucagon response to hypoglycemia is autonomically medi-
ated in humans.
The impairment of autonomic activation after recent hypo-
glycemia appears to be mediated by the increase of circulat-
ing cortisol evoked by antecedent episodes of hypoglycemia.
Cortisol, in turn, may impair autonomic activation (67) b y
producing a feedback inhibition of the central corticotropin-
releasing hormone (68) thought to be involved in mediating
sympathoadrenal activation during hypoglycemia (69). Evi-
dence for the role of cortisol includes induction of autonomic
and glucagon impairment by infusion of cortisol at rates that
mimic the plasma cortisol response to hypoglycemia (70) and
prevention of impaired autonomic and glucagon responses by
blocking the cortisol response to antecedent hypoglycemia
with metyrapone, an inhibitor of cortisol synthesis (71).
Up-regulation of brain glucose transport may be a separate
mechanism that reduces autonomic responses to hypogly-
cemia. This mechanism is likely to be prominent after long
repeated exposure to hypoglycemia, since those are the con-
ditions in which it has been demonstrated both in animals
(72,73) and in humans (74). Hypoglycemia-induced cortisol
secretion may also be involved in this mechanism of auto-
nomic impairment, since cortisol can induce up-regulation of
brain glucose transporters in animals (75). It should be
pointed out that up-regulation of brain glucose transport
would lessen central glucose deprivation, the stimulus for
autonomic activation, whereas the acute effects of cortisol,
mediated via suppression of central corticotropin-releasing
hormone, would inhibit autonomic outflow even in the pres-
ence of central glucopenia.
Additional indirect support for autonomic mediation in
humans is provided by studies in patients with chronic auto-
nomic dysfunction resulting from Chagas’s disease or Shy-
Drager syndrome. These patients have deficient parasympa-
thetic (PP) (76), adrenal medullary (epinephrine) (77), and
glucagon responses (76,77) to hypoglycemia. In contrast,
there are two studies that found that classical cholinergic and
adrenergic receptor antagonists did not reduce the glucagon
response to hypoglycemia in nondiabetic human subjects
(78,79). However, these antagonists block only the actions of
acetylcholine and catecholamines, but not the potential
actions of neuropeptides. It is possible that in humans, neu-
ropeptides such as VIP help mediate the glucagon response
to hypoglycemia. VIP is found in the parasympathetic nerves
(Fig. 2) of the human pancreas (80,81). In animal studies, VIP
is released from the pancreas during parasympathetic nerve
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stimulation (47) and during IIH (L. Benthem, T.O. Mundinger,
G . J . T., unpublished observations). Finally, local VIP infusion
increases glucagon secretion (46,47). Thus, VIP release from
pancreatic parasympathetic nerves during IIH could be a
mediator of the glucagon response to hypoglycemia in
humans. Such peptidergic neurotransmission would explain
the failure of classical cholinergic and adrenergic antagonists
to block the glucagon response and would reconcile those data
with autonomic mediation of the glucagon response.
An alternative explanation is that the lower doses of auto-
nomic blocking agents used in studies in humans (8,79) are
not sufficient to totally block the effects of the reflex auto-
nomic activation produced by hypoglycemia. For example,
the dose of atropine typically used in human studies (1 mg)
does not block a cardiovascular parasympathetic reflex (Va l-
salva); a fourfold higher dose is needed to suppress this
response (82). Thus, studies using different doses of auto-
nomic blockers might resolve these discrepancies between
human and animal studies.
Given the failure of adrenergic and muscarinic blockade to
reduce the glucagon response to hypoglycemia in humans,
other studies specifically designed to address the role of the
autonomic nervous system in nondiabetic humans were nec-
e s s a r y. In a recent study, the ganglionic blocker trimethaphan
was infused to impair autonomic activation in nondiabetic
human subjects. Trimethaphan impaired the increases of
plasma PP, epinephrine, and norepinephrine during hypogly-
cemia of 45 mg/dl by 70–80% and reduced the glucagon
response by 75% (Fig. 3). This study provides direct confim a-
tion of autonomic mediation in humans (83). Trimethaphan did
not affect the glucagon response to arginine, demonstrating
that this drug does not inhibit glucagon secretion directly
(83). Finally, it should be noted that ganglionic antagonists
block the pancreatic release of VIP from postganglionic
parasympathetic nerves (47). These data support the hypoth-
esis that activation of the autonomic nervous system has a
major role in mediating the glucagon response to hypogly-
cemia in nondiabetic humans.
GLUCAGON RESPONSE TO HYPOGLYCEMIA IN 
TYPE 1 DIABETES
Impaired -cell responses. The glucagon response to IIH
in patients with type 1 diabetes can be normal, impaired, or
totally absent. Before investigators started to examine the
effects of intensive insulin therapy, the available data sug-
gested that there was a progressive loss of this response
related to the duration of type 1 diabetes. For example, Bolli
et al. (15) showed that the glucagon response to IIH in certain
groups of newly diagnosed type 1 patients was quantitatively
normal, but that the response was clearly blunted in patients
who had type 1 diabetes for 1–5 years. Gerich et al. (84) had
demonstrated a decade earlier that the glucagon response to
IIH was absent in patients who had type 1 diabetes for over
a decade. These data suggested that type 1 diabetes per se
does not abolish the glucagon response to hypoglycemia,
but rather that a time-dependent factor associated with this
disease leads first to impairment and then to eventual loss of
this -cell response. A potential mechanism involving pro-
gressive autonomic neuropathy induced by chronic hyper-
glycemia is discussed below.
After clinical trials of intensive insulin therapy and the
associated increased incidence of hypoglycemia (2,3), m a n y
reports of impaired glucose counterregulation appeared
(10–13), even in patients with diabetes of short duration.
This impairment of glucose recovery was related to markedly
impaired glucagon (11,13) and epinephrine (12,13) responses
to hypoglycemia. There were also reports of a very early loss
of the glucagon response to hypoglycemia in newly diag-
nosed diabetic children (85,86). Reports of severe and pro-
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FIG. 3. PP, epinephrine, and glucagon concentrations in the peripheral
plasma of seven women before, during, and after a period of 2.5
mmol/l hypoglycemia (HYPOG; vertical dashed lines) during either a
saline infusion (— —) or ganglionic blockade with trimethaphan 
(– – ––). Adapted from Havel and Ahren (83).
longed nocturnal hypoglycemia in children (87) and of a
threefold increase in the incidence of hypoglycemia associ-
ated with intensive insulin therapy in adults (2,3) suggested
a contribution of prior hypoglycemia to this early loss of -
cell responses. A potential mechanism involving acute auto-
nomic dysfunction is discussed below.
M e c h a n i s m s
Hypoglycemia per se. The mechanism for the slow and pro-
gressive loss of the glucagon response to hypoglycemia in type
1 patients has been a subject of controversy. The loss is selec-
tive, i.e., patients with long-standing type 1 diabetes have
essentially no glucagon response to IIH yet have a normal
glucagon response to arginine (84). Thus, the secretory
capacity of the -cell is normal, yet the -cell is either unre-
sponsive to the stimuli specifically associated with IIH (see
below) or these stimuli are reduced in type 1 diabetes. As pre-
viously discussed, hypoglycemia per se, suppression of
endogenous insulin secretion, and activation of the auto-
nomic nervous system have all been proposed as mediators
of the stimulation of the glucagon response to hypoglycemia.
It is possible that an intrinsic defect in the - c e l l ’s response
to direct hypoglycemic stimulation is responsible for loss of
this -cell response in type 1 diabetes, as originally proposed
by Gerich et al. (84). Restoration of euglycemia in diabetic rats
does improve their glucagon responses to hypoglycemia (88)
consistent with a partially reversible defect in the - c e l l ’s
recognition of glucose that was induced by the chronic
hyperglycemia of diabetes. However, restoration of eugly-
cemia has also been shown to improve both residual - c e l l
function (89,90) and autonomic responses to hypoglycemia
(91). Thus, this observation is consistent with all three poten-
tial mediators of the glucagon response to hypoglycemia.
Loss of -cell function. The marked destruction of islet B-
cells that occurs at the onset of type 1 diabetes markedly
reduces endogenous insulin secretion (89,90), and thereby the
magnitude of the fall of endogenous insulin secretion normally
produced by hypoglycemia. Thus, that component of the
glucagon response hypothesized to occur secondary to sup-
pression of endogenous insulin should be markedly reduced
in diabetic islets (27,28) (Fig. 4A), unless the -cells become
more sensitive to endogenous insulin when the number of -
cells within the islet is dramatically reduced. Indeed, the -
cell seems to be more sensitive to exogenous insulin, since
the suppressive effect on the -cell becomes dominant (92)
when endogenous insulin is very low, as in the islets of
patients with C-peptide–negative diabetes (Fig. 4C ). Such
net suppression of glucagon secretion by endogenous insulin
is illustrated by the effect of hyperinsulinemic euglycemic
clamps to inhibit glucagon responses to arginine in patients
with type 1 diabetes (29). In contrast, the same level of
exogenous hyperinsulinemia potentiates the glucagon
response to arginine in nondiabetic subjects (29), presumably
via suppression of endogenous insulin secretion (29). Sur-
p r i s i n g l y, prior marked suppression of endogenous insulin
secretion does not potentiate the glucagon response to hypo-
glycemia (32), suggesting either that this mechanism is not
critical in nondiabetic humans or that complete suppression
of endogenous insulin, as occurs only during hypoglycemia
(32), is required. Nonetheless, the concept persists that in
patients with type 1 diabetes, a markedly reduced suppression
of endogenous insulin secretion, coupled with the unop-
posed inhibitory effect of exogenous insulin on the -cell, con-
tributes to the impairment of the glucagon response to IIH.
Some have even proposed that the progressive loss of the
-cell response to hypoglycemia in patients with type 1 dia-
betes is due to progressive loss of their residual -cell func-
tion (93). This hypothesis implies that many newly diagnosed
type 1 diabetic patients retain a small amount of -cell func-
tion, as has been documented both by residual insulin stain-
ing in one-third of the islets of autopsied pancreases (94)
and by residual C-peptide secretion in vivo (89,90). Some
patients may even regain -cell function upon institution of
therapy (95,96). Thus, if only a small percentage of the orig-
inal -cells are needed to retain -cell responsiveness to IIH,
these may still be present in many patients recently diag-
nosed with type 1 diabetes. Indeed, using a very sensitive C-
peptide assay to quantitate remaining -cell function, Fukuda
et al. (93) have demonstrated a correlation between the loss
of this residual -cell function and the loss of glucagon
responses to hypoglycemia (93) in type 1 diabetes. These
data support the hypothesis that impairment and eventual loss
of -cell responses to IIH are related to the loss of residual -
cell function in patients with type 1 diabetes.
Autonomic impairment. A l t e r n a t i v e l y, progressive impair-
ment of the autonomic responses to hypoglycemia may con-
tribute to the impairment (Fig. 4B) and eventual loss (Fig. 4C)
of the -cell response to hypoglycemia in type 1 diabetes.
Indeed, in the study noted above, the C-peptide nonrespon-
ders also had a delayed epinephrine response to IIH (93), sug-
gesting reduced autonomic input to the -cell. Even such
small impairments of the autonomic response to hypogly-
cemia could significantly reduce the glucagon response in
patients with type 1 diabetes if the unopposed inhibitory
action of exogenous insulin on the -cell renders it more
dependent on autonomic stimulation. Most investigators
have assumed, however, that autonomic dysfunction occurs
too late in the natural history of type 1 diabetes to contribute
to the relatively early impairment of the glucagon response
to IIH. This assumption is based on the common experience
that clinical diabetic autonomic neuropathy (DAN) usually
occurs after a decade or more of type 1 diabetes. However,
clinical DAN is usually recognized late in its course, in its
advanced and pervasive form (97), when it is associated with
postural hypotension.
More subtle, subclinical forms of neuropathy may be pres-
ent much earlier in the natural history of type 1 diabetes.
These may be detected with more sensitive autonomic tests,
such as measurement of heart rate variability (98), scintog-
raphy of the heart (99), and muscle sympathetic nerve activ-
ity (100). Indeed, one-half to three-fourths of patients with
type 1 diabetes who did not exhibit the usual signs of clinical
DAN had impaired autonomic function, as assessed by these
more sensitive tests (99–101). Other studies report the pres-
ence of subclinical autonomic neuropathy in one-half of all
patients with type 1 diabetes (97). Some of this autonomic dys-
function, however, may be unrelated to the autonomic inputs
to the -cell. Therefore, it is important to determine if the auto-
nomic responses to IIH per se are impaired in patients with
type 1 diabetes before the development of clinical DAN.
Results from a recent study have demonstrated just that: the
epinephrine and the PP responses to IIH are impaired in
patients that have type 1 diabetes without clinical signs of
DAN (102). Finally, it is important to recognize that the
response of the sympathetic nerves that innervate the - c e l l
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cannot currently be measured in humans, and thus the
impact of its potential impairment would not be ascribed to
the autonomic nervous system. Chemically induced or
immunologically mediated -cell destruction in rats is asso-
ciated with a marked decrease in the number of direct con-
tacts between sympathetic nerves and -cells (31), implying
a loss of -cell responsiveness to this autonomic input.
Indeed, this rapidly induced functional sympathetic dener-
vation of the -cell is associated with loss of glucagon
responses to glucopenia (31). This decrease in the number of
direct sympathetic contacts could simply be due to the
known shrinkage of the islet that occurs after -cell destruc-
tion. Alternately, recent studies have suggested that - c e l l s
secrete a neurotrophic factor that maintains sympathetic
innervation of the islet (103). Thus, the observation that loss
of residual -cell function is associated with loss of the
glucagon response to hypoglycemia may not be the exclusive
evidence for a role of endogenous insulin in the - c e l l
response to hypoglycemia that it first appeared to be. The
alternative, autonomic, interpretation is that loss of residual
-cells somehow widens the synaptic cleft between nerves
and -cells and, thereby, results in an impairment of the auto-
nomic stimulation of glucagon secretion during hypogly-
cemia in type 1 diabetes. We conclude that impairment of the
autonomic responses to IIH can occur well before the devel-
opment of clinical DAN and may contribute to the eventual
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FIG. 4. Type 1 diabetes. A: Basal glucagon levels in insulin-treated type 1 diabetes are either normal (thin arrow) or slightly elevated (not shown)
because of the near balance of stimulatory and inhibitory factors. The major stimulatory factor is a marked reduction of endogenous insulin
secretion (thin arrow) secondary to a major loss of -cells (
5
). The inhibitory factors on the -cell include the effects of 1) the exogenous
insulin used for treatment, 2) the hyperglycemia usually present despite insulin treatment, and 3) the lack of autonomic stimulation of the -
cell. B: In type 1 diabetes of 1–5 years’ duration, the glucagon response to hypoglycemia is usually blunted (medium arrow) compared with that
in nondiabetic subjects (Fig. 1), despite the direct stimulatory (+) effect of hypoglycemia on the -cell. The smaller glucagon response may
be due to a reduction of stimulatory factors, as well as increased sensitivity to inhibitory factors. Thus, there may be less autonomic stimu-
lation (+ +) of the -cell than in nondiabetic subjects because of chronic subclinical autonomic neuropathy and/or acute hypoglycemia-asso-
ciated autonomic dysfunction (see A U T O N O M I C I M PA I R M E N T). In addition, there is less stimulation of the -cell because the disinhibition by endoge-
nous insulin, present in the normal islet, has already been largely removed by the marked destruction of -cells (
5
). Finally, this chronic reduc-
tion of intraislet insulin levels may render the -cell more sensitive to the inhibitory effect (– –) of exogenous insulin. C: In type 1 diabetes
of 15–30 years’ duration, the glucagon response to hypoglycemia is usually absent (thin arrow). The loss of the glucagon response may be due
to further reductions of stimulatory factors, as well as to hypersensitivity to inhibitory factors. Thus, there is a further reduction of autonomic
stimulation (+) of the -cell (compare to Figs. 1 and 4B). There is also less stimulation of the -cell by suppression of endogenous insulin (
5
),
since after 15–30 years of type 1 diabetes, almost all -cells have disappeared. The very low levels of residual islet insulin may render the -cell
even more sensitive to the inhibitory effects (– – –) of exogenous insulin. - and -cells are represented as circles labeled A and B, respectively.
A
CB
loss (Fig. 4C), if not the original impairment (Fig. 4B), of the
glucagon response to IIH in patients with type 1 diabetes.
The rapid loss of glucagon responses to hypoglycemia in
patients intensively treated with insulin and in newly diag-
nosed children may be due to the “hypoglycemia-associated
autonomic failure” described by Cryer (4). In nondiabetic
subjects, this rapidly induced and reversible autonomic
impairment is associated with a reduction of the glucagon
response to subsequent hypoglycemia (64). Further, in dia-
betic animals with either induced or iatrogenic prior hypo-
glycemia, there is impairment of both the autonomic and
glucagon responses to subsequent hypoglycemia (66,104). It
is, therefore, plausible that antecedent hypoglycemia causes
an acute reduction of the autonomic stimulation to the - c e l l ,
which contributes to the impairment of the glucagon
response seen either in adult type 1 diabetic patients receiv-
ing intensive insulin therapy or in diabetic children who have
nocturnal hypoglycemia. To our knowledge, this hypothesis
has not been critically tested.
R E S T O R ATION OF GLUCAGON RESPONSES TO
H Y P O G LYCEMIA IN TYPE 1 DIABETES
Intensive insulin therapy. The total absence of a glucagon
response to IIH in patients who had type 1 diabetes for >15
years (15) led to the assumption that this loss may be irre-
versible. Indeed, in two groups with type 1 diabetes of 15–18
years duration, 3 months of intensive insulin therapy, with
meticulous avoidance of hypoglycemia, failed to improve
their epinephrine, PP, or glucagon responses to hypogly-
cemia (105). However, another study of patients with type 1
diabetes of only 4–7 years duration showed some improve-
ment, but not normalization, of the glucagon response to
hypoglycemia after similar therapy (91,106). It is noteworthy
that in these latter studies both the epinephrine and PP
responses, indices of autonomic inputs to the islet, were also
improved. Thus, intensive insulin therapy is associated with
partial restoration of autonomic responses to hypoglycemia,
and partial restoration of the glucagon responses to hypo-
glycemia, if the disease is not long standing. The partial
restoration of the autonomic responses is consistent with
partial reversal of subclinical autonomic neuropathy. Similar
conclusions have been reached concerning the influence of
duration of type 2 diabetes on the reversibility of defects in
autonomic function, such as nerve conduction velocity (107).
Pancreas transplantation. Glucagon responses to IIH have
also been examined in patients whose long-term type 1 dia-
betes has been corrected by pancreas transplantation
(51,108–110). Although successful pancreas transplantation
restores euglycemia (110,111), it is unlikely to restore the
responsiveness of the native -cells to hypoglycemia, since
most of these patients have had diabetes for nearly two
decades (108–111). Thus, any improvement seen in the
plasma glucagon response to hypoglycemia is assumed to be
due to the response of the -cells in the transplanted, rather
than the native, pancreas (109). Furthermore, the transplanted
pancreas should be autonomically denervated because surgi-
cal transplantation severs both the parasympathetic and the
sympathetic nerves that innervate the pancreas. Despite such
pancreatic denervation, the increment of plasma glucagon in
response to moderate hypoglycemia is similar to that seen in
normal control subjects (109,110). Furthermore, although the
secretion of the sympathetic neurohormone epinephrine still
increases during hypoglycemia, and although epinephrine can
still reach the -cells of the transplanted pancreas, it appears
to have little impact, since the glucagon response to hypogly-
cemia in transplant recipients is unaffected by - a d r e n e r g i c
blockade (109). The straightforward interpretation of these
data is that the glucagon response of the transplanted pancreas
is not autonomically mediated.
H o w e v e r, a more detailed analysis of the peripheral plasma
glucagon response in transplant recipients suggests that it
may be relatively impaired, consistent with denervation of th e
transplanted pancreas. This interpretation is based on the
recognition that most transplantation procedures provide
systemic, rather than portal, drainage for the pancreas. Such
drainage would eliminate the normal first-pass clearance of
glucagon by the liver (112,113) and thus be expected to
increase peripheral plasma levels of glucagon. Indeed, both
the basal concentrations of plasma glucagon (109,111) and the
glucagon response to arginine (109) are exaggerated in trans-
plant recipients. On this basis, one might have expected the
glucagon response to hypoglycemia in transplant recipients
to be exaggerated as well. Thus, the observation of a quanti-
tatively normal plasma glucagon response to hypoglycemia
in the transplant recipients might, in fact, reflect a relative
impairment of glucagon secretion. This interpretation is con-
sistent with the impairment of the small glucagon response
to mild hypoglycemia seen by other workers in transplant
recipients (51,108). Whatever interpretation is correct, the
impairment of the glucagon response in transplant recipi-
ents is not large, despite the autonomic denervation. Thus,
studies in recipients of pancreas transplants suggest that
nonautonomic mechanisms contribute substantially to the
glucagon response to hypoglycemia.
S U M M A RY, CONCLUSIONS, AND CLINICAL IMPLICAT I O N S
In this perspective, we have emphasized the role of the auto-
nomic nervous system in mediating the increase of glucagon
secretion observed during IIH. In 1989, when we reviewed
the evidence related to this hypothesis (33), we found only
a few studies in animals that supported an important role for
the autonomic nervous system and a number of studies in
humans that argued against this hypothesis. To reconcile
these conflicting data, we proposed that the three auto-
nomic inputs to the -cell (sympathetic nerves, parasympa-
thetic nerves, and the sympathetic neurohormone epineph-
rine [Fig. 2]) redundantly mediated the increase of glucagon
secretion during IIH in the absence of diabetes. In the sub-
sequent years, we performed a variety of experiments to
test that hypothesis using techniques to markedly reduce or
abolish the activation of all three of these autonomic inputs
during hypoglycemia; we found a marked reduction of the
glucagon response in several species (55,56,62,63), including
nonhuman primates (57) and, recently, humans (83). Stud-
ies by other investigators (59–61) in which central auto-
nomic activation was prevented also demonstrated a
markedly reduced glucagon response. We conclude that
although peripheral hypoglycemia and suppression of
endogenous insulin secretion may be permissive for a nor-
mal glucagon response to IIH, the majority of this glucagon
response is mediated by redundant autonomic stimulation
of the islet - c e l l .
Because it now appears that autonomic mediation is an
important determinant of the glucagon response to hypogly-
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cemia in humans, we propose here that autonomic impair-
ment, together with -cell destruction, contributes to the
loss of this glucagon response in type 1 diabetes. Specifi-
c a l l y, the slow and progressive loss of the glucagon response
to hypoglycemia that can occur during the first decade of type
1 diabetes may be due to a progressive impairment of the auto-
nomic responses to hypoglycemia secondary to the devel-
opment of subclinical DAN. This hypothesis is clinically rel-
evant because early autonomic neuropathy may be more
functional than anatomic and may, therefore, be reversible if
treated promptly. Indeed, correcting hyperglycemia does par-
tially restore the autonomic and glucagon responses to IIH in
patients with type 1 diabetes of short (91,106), but not long
(105), duration. A second clinical implication is that agents
used to treat or prevent neuropathy should also improve the
glucagon response or prevent its impairment, a hypothesis
that is currently untested.
An acute form of autonomic dysfunction has recently been
recognized: autonomic responses to hypoglycemia can be
rapidly impaired by recent episodes of antecedent hypogly-
cemia (64,65). The autonomic hypothesis implies that this
type of autonomic dysfunction should also impair the - c e l l
response in nondiabetic individuals, which it does (64). It
also implies that acute autonomic dysfunction will further
blunt the glucagon response in patients with short-term type
1 diabetes. Although this latter hypothesis has not been
tested, if it is true, then intensive insulin therapy, which can
produce inadvertent hypoglycemia and thus acute autonomic
dysfunction, may actually worsen the -cell response in
patients with type 1 diabetes. Thus, efforts to reduce diabetic
hyperglycemia should be coupled with meticulous avoidance
of hypoglycemia (91,105,106). Rapid restoration of autonomic
and glucagon responses would then reflect reversal of the
acute autonomic dysfunction induced by prior episodes of
hypoglycemia, while slower restoration would reflect reversal
of those functional defects in peripheral autonomic nerves
caused by chronic hyperglycemia. The acute autonomic dys-
function should be fully reversible, while the subclinical auto-
nomic neuropathy may only be partially reversible, particularly
if there are structural defects in autonomic nerves induced by
either long-term hyperglycemia or total -cell destruction.
Indeed, successful pancreas transplantation, which can
restore euglycemia without inducing hypoglycemia, only par-
tially corrects defects in nerve conduction velocity in patients
with long-term type 1 diabetes (114). Finally, it is appropriate
to reemphasize that the role of autonomic impairment in the
d e ficient glucagon response in patients with type 1 diabetes
remains speculative. However, based on the recent evidence
for autonomic mediation in nondiabetic humans (83) and
given the important implications of this mechanism for
restoration of glucagon responses and glucose counterregu-
lation in type 1 diabetes, we feel that expenditure of serious
effort to directly test this hypothesis is warranted.
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